Possibilities of Azilsartan Medoxomil for Preparation for Planned Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus
Open Access
- 31 July 2024
- journal article
- research article
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (7) , 48-55
Abstract
Aim . To evaluate the efficacy and safety of azilsartan medoxomil for preoperative preparation and improving the long-term prognosis of elective percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD), arterial hypertension (AH), and type 2 diabetes mellitus (DM). Material and methods . The study sample included patients with type 2 DM referred for elective PCI who had poor blood pressure (BP) control according to 24-hour BP monitoring (24-BPM) (mean daily systolic BP ≥130 mmHg, mean daily diastolic BP ≥80 mmHg). The data were collected from 2018 through 2020. A total of 75 patients was included and distributed by simple randomization into two groups: group 1 (main, n=37) received azilsartan medoxomil as an antihypertensive drug at a dose of 40 mg/day (previously prescribed angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ARB) were discontinued); group 2 (control, n=38) continued on their previous antihypertensive therapy. The follow-up period was 6 months. During each of 5 consecutive follow-up visits, the patient was examined, 24-BPM was recorded, and urinary markers of renal dysfunction (glomerular filtration rate, GFR; neutrophil gelatinase-associated lipocalin, NGAL; urine albumin-creatinine ratio, UACR; kidney injury molecule, KIM-1; and interleukin-18, IL-18) were measured. Results . During the azilsartan treatment, GFR decreased by 7.4%, while in the control group, it decreased by 18.9% (pConclusion . This study demonstrated two important facts: the possibility for diagnosing contrast-induced acute kidney injury (CI-AKI) using new, more sensitive markers of kidney damage, which is important for assessing the effectiveness of prevention, and the possibility of using ARBs, in particular azilsartan, for the prevention of CI-AKI in patients with IHD in combination with AH and DM.Keywords
This publication has 11 references indexed in Scilit:
- Atherosclerosis Specific Features in Chronic Kidney Disease (CKD)Biomedicines, 2022
- The Pathophysiology and the Management of Radiocontrast-Induced NephropathyDiagnostics, 2022
- Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysisJournal of International Medical Research, 2021
- A novel risk assessment model of contrast‐induced nephropathy after percutaneous coronary intervention in patients with diabetesBasic & Clinical Pharmacology & Toxicology, 2020
- Development and Validation of a Model for Predicting the Risk of Acute Kidney Injury Associated With Contrast Volume Levels During Percutaneous Coronary InterventionJAMA Network Open, 2019
- ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTIONRational Pharmacotherapy in Cardiology, 2017
- EFFICACY OF AZILSARTAN MEDOXOMIL ON THE DAILY PROFILE OF PERIPHERAL AND CENTRAL ARTERIAL PRESSURE AND ARTERIAL STIFFNESS IN HYPERTENSIVES WITH TYPE 2 DIABETESCardiovascular Therapy and Prevention, 2017
- Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the National Cardiovascular Data Registry Cath‐PCI RegistryJournal of the American Heart Association, 2014
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- Impact of Preoperative Angiotensin-Converting Enzyme Inhibitor Use on Clinical Outcomes After Cardiac SurgeryThe Annals of Thoracic Surgery, 2012